Dr. Karen Walters, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 167 Washington Ave, Little Ferry, NJ 07643 Phone: 201-641-1600 Fax: 201-807-0231 |
Michael Anthony Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 198 Main Street, Little Ferry, NJ 07643 Phone: 201-440-8884 |
Little Ferry Sports, Spine & Rehabilitation Center Chiropractor Medicare: Medicare Enrolled Practice Location: 167 Washington Ave, Little Ferry, NJ 07643 Phone: 201-641-1600 Fax: 201-807-0231 |
Little Ferry Sports And Rehab Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 167 Washington Ave, Little Ferry, NJ 07643 Phone: 201-641-1600 Fax: 201-807-0231 |
Little Ferry Chiropractic And Physical Therapy Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 167 Washington Ave, Little Ferry, NJ 07643 Phone: 201-641-1600 Fax: 201-807-0231 |
Dr. Charles Michael Terranova, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 167 Washington Ave, Little Ferry, NJ 07643 Phone: 201-641-1600 Fax: 201-807-0231 |
News Archive
Researchers at the Johns Hopkins Bloomberg School of Public Health have identified a gene in the Anopheles gambiae mosquito's DNA that is central to the insect's ability to defend against infectious pathogens, including Plasmodium, the parasite that causes malaria in humans.
Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain "off-label" therapeutic uses.
Watching the brain's "autopilot" network in real time may help determine the onset of cognitive decline and potentially aid in making an early diagnosis of Alzheimer's disease, according to researchers at Duke University Medical Center.
FICO, the leading provider of analytics and decision management technology, and Emdeon Inc, a leading provider of healthcare revenue and payment cycle management solutions, today announced a commercial agreement aimed at preventing fraud, waste and abuse in the health insurance system.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
› Verified 3 days ago